## Thanyawee Puthanakit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2403674/publications.pdf

Version: 2024-02-01

206 papers

4,163 citations

147566 31 h-index 149479 56 g-index

211 all docs

211 docs citations

times ranked

211

4213 citing authors

#	Article	IF	CITATIONS
1	Diagnostic Accuracy of Loop-Mediated Isothermal Amplification (TB-LAMP) for Tuberculosis in Children. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 9-15.	0.6	4
2	Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pacific Journal of Allergy and Immunology, 2022, , .	0.2	20
3	Prevention of Emerging Infections in Children. Pediatric Clinics of North America, 2022, 69, 185-202.	0.9	2
4	A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age. Vaccine, 2022, 40, 2352-2361.	1.7	2
5	Seroprevalence of mumps among children and adolescents in Thailand, 2020. Vaccine, 2022, 40, 1061-1064.	1.7	1
6	A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. Vaccine, 2022, 40, 2551-2560.	1.7	11
7	Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines, 2022, 10, 639.	2.1	18
8	A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2022, 10, e25561.	1.8	9
9	Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. Vaccines, 2022, 10, 871.	2.1	13
10	Retention in event-driven PrEP among young Thai men who have sex with men at risk of HIV acquisition. International Journal of STD and AIDS, 2022, 33, 799-805.	0.5	3
11	Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings. Journal of Infectious Diseases, 2022, 226, 374-385.	1.9	10
12	Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 419-427.	0.3	O
13	Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 427-438.	2.9	13
14	Identification, Management, and Outcomes of Combination Antiretroviral Treatment Failure in Adolescents With Perinatal Human Immunodeficiency Virus Infection in Asia. Clinical Infectious Diseases, 2021, 73, e1919-e1926.	2.9	2
15	CD4/CD8 Ratio Recovery of Children and Adolescents Living With HIV With Virological Suppression: A Prospective Cohort Study. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 88-96.	0.6	5
16	Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand. Influenza and Other Respiratory Viruses, 2021, 15, 64-71.	1.5	13
17	Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 21-32.	5.2	74
18	HIV-related enacted stigma and increase frequency of depressive symptoms among Thai and Cambodian adolescents and young adults with perinatal HIV. International Journal of STD and AIDS, 2021, 32, 246-256.	0.5	4

#	Article	IF	CITATIONS
19	High prescribing rates of third-generation cephalosporins in children hospitalized with acute lower respiratory infections at a university hospital. International Journal of Infectious Diseases, 2021, 102, 369-374.	1.5	3
20	Behavioral impairment and cognition in Thai adolescents affected by HIV. Global Mental Health (Cambridge, England), 2021, 8, e3.	1.0	3
21	Integration of mental health services into HIV healthcare facilities among Thai adolescents and young adults living with HIV. Journal of the International AIDS Society, 2021, 24, e25668.	1.2	11
22	Acceptance and Outcome of Interventions in Meropenem Deâ€escalation ASP in Pediatrics. Pediatrics International, 2021, 63, 1458-1465.	0.2	3
23	Acceptability of blood-based HIV self-testing among adolescents aged 15–19 years at risk of HIV acquisition in Bangkok. International Journal of STD and AIDS, 2021, 32, 927-932.	0.5	7
24	No increased acute kidney injury rate through giving an intravenous colistin loading dose in pediatric patients. International Journal of Infectious Diseases, 2021, 106, 91-97.	1.5	2
25	Response of Severe EV71-Infected Patients to Hyperimmune Plasma Treatment: A Pilot Study. Pathogens, 2021, 10, 625.	1.2	2
26	Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial. Clinical Infectious Diseases, 2021, 73, 1555-1564.	2.9	9
27	Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV. Journal of the International AIDS Society, 2021, 24, e25759.	1.2	14
28	Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients. International Journal of Infectious Diseases, 2021, 108, 102-108.	1.5	6
29	Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age. Pediatric Infectious Disease Journal, 2021, 40, e333-e339.	1.1	8
30	Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study. International Journal of Infectious Diseases, 2021, 109, 230-237.	1.5	3
31	Federated learning for predicting clinical outcomes in patients with COVID-19. Nature Medicine, 2021, 27, 1735-1743.	15.2	300
32	Immunogenicity of 2-dose pre-exposure rabies vaccine co-administered with quadrivalent influenza vaccine in children. International Journal of Infectious Diseases, 2021, 112, 89-95.	1.5	2
33	High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy. Vaccine, 2021, 39, 6206-6209.	1.7	2
34	ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infectious Diseases, 2021, 21, 5.	1.3	26
35	Adaptation of a Theory-Based Social Networking and Gamified App-Based Intervention to Improve Pre-Exposure Prophylaxis Adherence Among Young Men Who Have Sex With Men in Bangkok, Thailand: Qualitative Study. Journal of Medical Internet Research, 2021, 23, e23852.	2.1	6
36	Pediatric and Neonatal Invasive Candidiasis. Pediatric Infectious Disease Journal, 2021, 40, 96-102.	1.1	3

#	Article	IF	CITATIONS
37	Behavioral problems in perinatally HIV-infected young children with early antiretroviral therapy and HIV-exposed uninfected young children: prevalence and associated factors. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 429-437.	0.6	5
38	Machine-learning classification of neurocognitive performance in children with perinatal HIV initiating de novo antiretroviral therapy. Aids, 2020, 34, 737-748.	1.0	12
39	Gaps in the elimination of congenital syphilis in a tertiary care center in Thailand. Pediatrics International, 2020, 62, 330-336.	0.2	6
40	Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons. Pediatric Infectious Disease Journal, 2020, 39, e1-e10.	1.1	23
41	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS ONE, 2020, 15, e0240502.	1.1	68
42	Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV preâ€exposure prophylaxis. Journal of the International AIDS Society, 2020, 23, e25624.	1.2	7
43	Determining standardized causes of death of infants, children, and adolescents living with HIV in Asia. Aids, 2020, 34, 1527-1537.	1.0	9
44	Rapid antiretroviral initiation among Thai youth living with HIV in the National AIDS programme in the era of treatment at any CD4 cell count: a national registry database study. Journal of the International AIDS Society, 2020, 23, e25574.	1.2	8
45	Skin manifestations in COVIDâ€19: The tropics experience. Journal of Dermatology, 2020, 47, e444-e446.	0.6	9
46	Youthâ€friendly services and a mobile phone application to promote adherence to preâ€exposure prophylaxis among adolescent men who have sex with men and transgender women atâ€risk for HIV in Thailand: a randomized control trial. Journal of the International AIDS Society, 2020, 23, e25564.	1.2	23
47	Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium. Journal of the International AIDS Society, 2020, 23, e25580.	1.2	5
48	Efficacy of chlorhexidine patches on central lineâ€associated bloodstream infections in children. Pediatrics International, 2020, 62, 789-796.	0.2	3
49	Pattern and Frequency of Seroreactivity to Routinely Used Serologic Tests in Early-Treated Infants With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 260-266.	0.9	2
50	Implementation of an active case management network to identify HIVâ€positive infants and accelerate the initiation of antiretroviral therapy, Thailand 2015 to 2018. Journal of the International AIDS Society, 2020, 23, e25450.	1.2	2
51	Antimicrobial prescription patterns in a tertiaryâ€care pediatric unit in Thailand. Pediatrics International, 2020, 62, 683-687.	0.2	4
52	Husband's willingness-to-pay for HIV and syphilis screening at antenatal care clinic under the Thai universal coverage scheme. BMC Public Health, 2020, 20, 480.	1.2	1
53	Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients. International Journal of Antimicrobial Agents, 2020, 55, 105940.	1.1	6
54	Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial. Clinical and Experimental Pediatrics, 2020, 63, 265-271.	0.9	1

#	Article	IF	CITATIONS
55	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019., 2020, 15, e0240502.		O
56	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. , 2020, 15, e0240502.		0
57	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019., 2020, 15, e0240502.		0
58	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019., 2020, 15, e0240502.		0
59	Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia. Journal of Adolescent Health, 2019, 65, 651-659.	1.2	O
60	Implementation of "Treatâ€all―at adult <scp>HIV</scp> care and treatment sites in the Global le <scp>DEA</scp> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	1.2	32
61	Optimizing Vancomycin Use Through 2â€Point AUCâ€Based Therapeutic Drug Monitoring in Pediatric Patients. Journal of Clinical Pharmacology, 2019, 59, 1597-1605.	1.0	19
62	A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children. Vaccine, 2019, 37, 5307-5313.	1.7	3
63	Strong sex bias in elite control of paediatric HIV infection. Aids, 2019, 33, 67-75.	1.0	22
64	Mapping abnormal subcortical neurodevelopment in a cohort of Thai children with HIV. NeuroImage: Clinical, 2019, 23, 101810.	1.4	11
65	Low risk of neurodevelopmental impairment among perinatally acquired <scp>HIV</scp> â€infected preschool children who received early antiretroviral treatment in Thailand. Journal of the International AIDS Society, 2019, 22, e25278.	1.2	10
66	Disease- and Treatment-related Morbidity in Adolescents With Perinatal HIV Infection in Asia. Pediatric Infectious Disease Journal, 2019, 38, 287-292.	1.1	7
67	Where latest advances in HIV are shared: 21st Bangkok International Symposium on HIV Medicine. Future Virology, 2019, 14, 129-132.	0.9	O
68	Barriers to paediatric switching to second-line ART. Lancet HIV, the, 2019, 6, e71-e72.	2.1	1
69	Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821882325.	0.6	3
70	Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS Program. Journal of Virus Eradication, 2019, 5, 33-40.	0.3	6
71	2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study. Open Forum Infectious Diseases, 2019, 6, S74-S75.	0.4	0
72	Trajectory Analysis of Cognitive Outcomes in Children With Perinatal HIV. Pediatric Infectious Disease Journal, 2019, 38, 1038-1044.	1.1	7

#	Article	IF	Citations
73	Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. PLoS ONE, 2019, 14, e0226375.	1.1	10
74	Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. Pediatric Infectious Disease Journal, 2019, 38, 1045-1050.	1.1	4
75	Emotional and behavioral resilience among children with perinatally acquired HIV in Thailand and Cambodia. Aids, 2019, 33, S17-S27.	1.0	12
76	Increased Risk of Executive Function and Emotional Behavioral Problems Among Virologically Well-Controlled Perinatally HIV-Infected Adolescents in Thailand and Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 297-304.	0.9	16
77	Dual Analysis of Loss to Follow-up for Perinatally HIV-Infected Adolescents Receiving Combination Antiretroviral Therapy in Asia. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 431-438.	0.9	1
78	Clinical Presentation of Influenza in Children 6 to 35 Months of Age. Pediatric Infectious Disease Journal, 2019, 38, 866-872.	1.1	17
79	Reduced Time to Suppression Among Neonates With HIV Initiating Antiretroviral Therapy Within 7 Days After Birth. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 483-490.	0.9	7
80	Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis. Pediatric Infectious Disease Journal, 2019, 38, 152-156.	1.1	2
81	Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS Program. Journal of Virus Eradication, 2019, 5, 33-40.	0.3	1
82	Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. Antiviral Therapy, 2018, 23, 259-265.	0.6	1
83	Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. New England Journal of Medicine, 2018, 378, 911-923.	13.9	226
84	Structural Neuroimaging and Neuropsychologic Signatures in Children With Vertically Acquired HIV. Pediatric Infectious Disease Journal, 2018, 37, 662-668.	1.1	13
85	Cognition, Emotional Health, and Immunological Markers in Children With Long-Term Nonprogressive HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 417-426.	0.9	10
86	Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. The Lancet Child and Adolescent Health, 2018, 2, 338-349.	2.7	51
87	Prevalence of Persistent Renal Dysfunction in Perinatally HIV-infected Thai Adolescents. Pediatric Infectious Disease Journal, 2018, 37, 66-70.	1.1	4
88	Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S40-S48.	0.9	7
89	Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B. Obstetrical and Gynecological Survey, 2018, 73, 443-445.	0.2	1
90	A Global Research Agenda for Pediatric HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S10-S15.	0.9	22

#	Article	IF	Citations
91	Effect of calcium and vitamin D supplementation on bone mineral accrual among HIV-infected Thai adolescents with low bone mineral density. Journal of Virus Eradication, 2018, 4, 6-11.	0.3	7
92	A Global Research Agenda for Adolescents Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S16-S21.	0.9	56
93	HIV medicine as double-sided sword: care and prevention. Future Virology, 2018, 13, 313-316.	0.9	0
94	Effect of calcium and vitamin D supplementation on bone mineral accrual among HIV-infected Thai adolescents with low bone mineral density. Journal of Virus Eradication, 2018, 4, 6-11.	0.3	5
95	Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Vaccine, 2017, 35, 299-304.	1.7	18
96	Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents. Pediatric Infectious Disease Journal, 2017, 36, 967-972.	1.1	8
97	Attrition and Mortality of Children Receiving Antiretroviral Treatment through the Universal Coverage Health Program in Thailand. Journal of Pediatrics, 2017, 188, 210-216.e1.	0.9	11
98	First-Line Antiretroviral Treatment Outcomes and Durability in HIV-Infected Children Treated Through the Universal Coverage Health Program in Thailand. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 219-225.	0.9	2
99	Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 ASO4-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. Journal of Infectious Diseases, 2017, 215, 1711-1719.	1.9	22
100	Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents. Pediatric Infectious Disease Journal, 2017, 36, 401-404.	1.1	2
101	Adolescents with HIV and transition to adult care in the Caribbean, Central America and South America, Eastern Europe and Asia and Pacific regions. Journal of the International AIDS Society, 2017, 20, 21475.	1.2	37
102	Decades research and implementation science of HIV prevention, treatment and cure: highlights from Symposium 2017. Future Virology, 2017, 12, 247-251.	0.9	2
103	Prevalence and Characteristics of Pediatric Healthcare Workers without Immunity to Varicella zoster Virus. Japanese Journal of Infectious Diseases, 2017, 70, 216-218.	0.5	1
104	The 10-Year Effectiveness of Combination Antiretroviral Treatment in Perinatally HIV-Infected Children Participating in Thailand's National Access Program. Antiviral Therapy, 2016, 21, 261-265.	0.6	2
105	Hypovitaminosis D and hyperparathyroidism. Aids, 2016, 30, 1059-1067.	1.0	14
106	Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents. Antiviral Therapy, 2016, 22, 471-479.	0.6	8
107	Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infectious Diseases, 2016. 16. 393.	1.3	29
108	Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. Vaccine, 2016, 34, 5279-5283.	1.7	9

#	Article	IF	Citations
109	Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. Journal of Infectious Diseases, 2016, 214, 525-536.	1.9	36
110	Final Height and Associated Factors in Perinatally HIV-infected Asian Adolescents. Pediatric Infectious Disease Journal, 2016, 35, 201-204.	1.1	16
111	Ending AIDS and challenges for Asia. Future Virology, 2015, 10, 341-345.	0.9	O
112	Brain Imaging and Neurodevelopment in HIV-uninfected Thai Children Born to HIV-infected Mothers. Pediatric Infectious Disease Journal, 2015, 34, e211-e216.	1.1	23
113	A slow progressor HIV-infected boy developing quadriplegia with evidence of Epstein-Barr virus associated smooth muscle tumour of the cervical spinal cord. BMJ Case Reports, 2015, 2015, bcr2015210133.	0.2	2
114	Review of Tenofovir Use in HIV-infected Children. Pediatric Infectious Disease Journal, 2015, 34, 383-391.	1.1	28
115	APOBEC3G genotypes and proviral DNA hypermutations on HIV/AIDS disease progression in Thai and Cambodian children. Future Virology, 2015, 10, 1267-1274.	0.9	1
116	HLA-DRB1454 and predictors of new-onset asthma in HIV-infected Thai children. Clinical Immunology, 2015, 157, 26-29.	1.4	3
117	Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. Journal of Virus Eradication, 2015, 1, 196-202.	0.3	13
118	Barriers and best practices of transitioning perinatally HIV-infected adolescents to adult care in Asia-Pacific. Journal of Virus Eradication, 2015, 1, 284-5.	0.3	1
119	Adverse bone health among children and adolescents growing up with HIV. Journal of Virus Eradication, 2015, 1, 159-67.	0.3	3
120	Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. Journal of Virus Eradication, 2015, 1, 185-91.	0.3	0
121	HIV disclosure and its effect on treatment outcomes in perinatal HIV-infected Thai children. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1144-1149.	0.6	27
122	Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1327-1335.	0.6	79
123	Comparison of Adherence Monitoring Tools and Correlation to Virologic Failure in a Pediatric HIV Clinical Trial. AIDS Patient Care and STDs, 2014, 28, 296-302.	1.1	17
124	Simplifying Antiretroviral Therapy to Lopinavir/Ritonavir Monotherapy Did Not Improve Quality of Life and Therapy Adherence in Pretreated HIV-Infected Children. AIDS Research and Human Retroviruses, 2014, 30, 260-265.	0.5	2
125	Pharmacokinetics of Atazanavir/Ritonavir Among HIV-infected Thai Children Concomitantly Taking Tenofovir Disoproxil Fumarate. Pediatric Infectious Disease Journal, 2014, 33, e316-e319.	1.1	5
126	Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. Aids, 2014, 28, 1015-1020.	1.0	108

#	Article	IF	CITATIONS
127	Impact of Antiretroviral Therapy on Opportunistic Infections of HIV-infected Children in the Therapeutic Research, Education and AIDS Training Asia Pediatric HIV Observational Database. Pediatric Infectious Disease Journal, 2014, 33, 747-752.	1.1	20
128	Association between lymphocyte and monocyte subsets and cognition in children with HIV. AIDS Research and Therapy, 2014, 11, 7.	0.7	2
129	Comparing Interferon-Gamma Release Assays to Tuberculin Skin Test in Thai Children with Tuberculosis Exposure. PLoS ONE, 2014, 9, e105003.	1.1	17
130	Double-Dose Hepatitis B Revaccination in Nonresponsive HIV-Infected Adolescents. Journal of the International Association of Providers of AIDS Care, 2013, 12, 157-158.	0.6	1
131	Prevalence of Vitamin D Deficiency Among Perinatally HIV-infected Thai Adolescents Receiving Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2013, 32, 1237-1239.	1.1	18
132	Impact of Antiretroviral Therapy on Quality of Life in HIV-Infected Southeast Asian Children in the PREDICT Study. AIDS Patient Care and STDs, 2013, 27, 596-603.	1.1	22
133	Second-line protease inhibitor-based highly active antiretroviral therapy after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children. Antiviral Therapy, 2013, 18, 591-598.	0.6	10
134	The 16th Bangkok International Symposium on HIV Medicine. Future Virology, 2013, 8, 331-333.	0.9	0
135	Cognitive Function and Neurodevelopmental Outcomes in HIV-infected Children Older Than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2013, 32, 501-508.	1.1	138
136	Long-term Lopinavir/Ritonavir Monotherapy in HIV-infected Children. Pediatric Infectious Disease Journal, 2013, 32, 350-353.	1.1	9
137	Bone health in children and adolescents with perinatal HIV infection. Journal of the International AIDS Society, 2013, 16, 18575.	1.2	30
138	Prevalence of Human Leukocyte Antigen-B*5701 Among HIV-infected Children in Thailand and Cambodia. Pediatric Infectious Disease Journal, 2013, 32, 252-253.	1.1	15
139	Immunoglobulin values in healthy Thai children aged â‰\$24 months determined by nephelometry. Asian Pacific Journal of Allergy and Immunology, 2013, 31, 307-13.	0.2	3
140	A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine. Clinical Infectious Diseases, 2012, 54, 285-293.	2.9	19
141	Poor quality of life among untreated Thai and Cambodian children without severe HIV symptoms. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 30-38.	0.6	10
142	Pharmacokinetics of Darunavir/Ritonavir in Asian HIV-1-Infected Children Aged ≥7 Years. Antiviral Therapy, 2012, 17, 1263-1269.	0.6	1
143	The 15th Bangkok International Symposium on HIV Medicine. Future Virology, 2012, 7, 341-344.	0.9	0
144	Recovery From Lipodystrophy in HIV–infected Children After Substitution of Stavudine With Zidovudine in a Non-nucleoside Reverse Transcriptase Inhibitor–based Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2012, 31, 384-388.	1.1	17

#	Article	IF	CITATIONS
145	HIV and Hepatitis B Coinfection Among Perinatally HIV-infected Thai Adolescents. Pediatric Infectious Disease Journal, 2012, 31, 943-947.	1.1	19
146	Prevalence and Risk Factors of Low Bone Mineral Density Among Perinatally HIV-Infected Thai Adolescents Receiving Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 477-483.	0.9	36
147	Prevalence of Anemia and Underlying Iron Status in Naive Antiretroviral Therapy HIV-Infected Children with Moderate Immune Suppression. AIDS Research and Human Retroviruses, 2012, 28, 1679-1686.	0.5	11
148	High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Research and Therapy, 2012, 9, 20.	0.7	15
149	Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency. AIDS Research and Therapy, 2012, 9, 34.	0.7	11
150	Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infectious Diseases, The, 2012, 12, 933-941.	4.6	78
151	Nephelometry determined serum immunoglobulin isotypes in healthy Thai children aged 2–15 years. Microbiology and Immunology, 2012, 56, 117-122.	0.7	4
152	Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine, 2011, 29, 2962-2967.	1.7	19
153	Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine, 2011, 29, 3977-3981.	1.7	20
154	The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine, 2011, 29, 5886-5891.	1.7	15
155	High Prevalence of Lipid Abnormalities among Antiretroviral-Naive HIV-Infected Asian Children with Mild-To-Moderate Immunosuppression. Antiviral Therapy, 2011, 16, 1351-1355.	0.6	19
156	Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children. Aids, 2011, 25, 315-323.	1.0	7
157	The Immunogenicity and Safety of Live Attenuated Varicella-zoster Virus Vaccine in Human Immunodeficiency Virus-infected Children. Pediatric Infectious Disease Journal, 2011, 30, 320-324.	1.1	39
158	Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. Aids, 2011, 25, 1143-1151.	1.0	18
159	The 14th Bangkok International Symposium on HIV Medicine. Future Virology, 2011, 6, 409-412.	0.9	O
160	Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents. Antiviral Therapy, 2011, 17, 283-289.	0.6	2
161	Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children. AIDS Research and Therapy, 2011, 8, 40.	0.7	39
162	Cohort Profile: The TREAT Asia Pediatric HIV Observational Database. International Journal of Epidemiology, 2011, 40, 15-24.	0.9	50

#	Article	IF	CITATIONS
163	Survival of HIV-Infected Children: A Cohort Study From the Asia-Pacific Region. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 365-371.	0.9	30
164	Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings. Current Pediatric Reviews, 2011, 7, 180-187.	0.4	0
165	Antiretroviral Therapy Outcomes of HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 503-509.	0.9	38
166	Early versus deferred antiretroviral therapy in children in low-income and middle-income countries. Current Opinion in HIV and AIDS, 2010, 5, 12-17.	1.5	11
167	THERAPEUTIC DRUG MONITORING OF LOPINAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN RECEIVING ADULT TABLETS. Pediatric Infectious Disease Journal, 2010, 29, 79-82.	1.1	8
168	MEASLES OUTBREAK IN AN ORPHANAGE. Pediatric Infectious Disease Journal, 2010, 29, 167-169.	1.1	3
169	CD4 CELL COUNT CRITERIA TO DETERMINE WHEN TO INITIATE ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN. Pediatric Infectious Disease Journal, 2010, 29, 966-968.	1.1	6
170	Predictors of Treatment Failure in Cambodian Children With Human Immunodeficiency Virus Infection. Pediatric Infectious Disease Journal, 2010, 29, 581.	1.1	0
171	The 13th Bangkok International Symposium on HIV Medicine. HIV Therapy, 2010, 4, 135-137.	0.6	О
172	Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected childrenauthors' response. Journal of Antimicrobial Chemotherapy, 2010, 65, 809-810.	1.3	0
173	Persistence of Measles, Mumps, and Rubella Protective Antibodies 3 Years after Revaccination in HIVâ€Infected Children Receiving Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 50, 1415-1418.	2.9	31
174	Poor Cognitive Functioning of School-Aged Children in Thailand with Perinatally Acquired HIV Infection Taking Antiretroviral Therapy. AIDS Patient Care and STDs, 2010, 24, 141-146.	1.1	61
175	Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12Âyears of age. Journal of Allergy and Clinical Immunology, 2010, 126, 1294-1301.e10.	1.5	29
176	A 3-year follow-up of antibody response in HIV-infected children with immune recovery vaccinated with inactivated Japanese encephalitis vaccine. Vaccine, 2010, 28, 5900-5902.	1.7	11
177	Corrigendum to "Antibody response to hepatitis B virus re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy―[Vaccine 2007;25:5324–9]. Vaccine, 2010, 28, 8224.	1.7	0
178	Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. International Journal of Infectious Diseases, 2010, 14, e311-e316.	1.5	4
179	Thai national guidelines for the use of antiretroviral therapy in pediatric HIV infection in 2010. Asian Biomedicine, 2010, 4, 505-513.	0.2	16
180	Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women. Antimicrobial Agents and Chemotherapy, 2009, 53, 2189-2191.	1.4	6

#	Article	IF	CITATIONS
181	Reversal of Growth Failure in HIV-Infected Thai Children Treated with Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy. AIDS Patient Care and STDs, 2009, 23, 1067-1071.	1.1	21
182	Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2009, 64, 1080-1086.	1.3	20
183	Henoch–Schönlein purpura and thrombocytopenia after planned antiretroviral treatment interruption in a Thai girl with HIV infection. International Journal of Infectious Diseases, 2009, 13, e31-e33.	1.5	13
184	Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2009, 28, 826-830.	1.1	63
185	Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2009, 28, 488-492.	1.1	51
186	EFFICACY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN THAI HIV-INFECTED CHILDREN AGED TWO YEARS OR LESS. Pediatric Infectious Disease Journal, 2009, 28, 246-248.	1.1	15
187	The 12th Bangkok International Symposium on HIV Medicine. HIV Therapy, 2009, 3, 225-227.	0.6	0
188	Dilated cardiomyopathy in three HIVâ€infected children after initiation of antiretroviral therapy. Pediatrics International, 2008, 50, 251-254.	0.2	5
189	Lessons from a multicentre paediatric HIV trial. Lancet, The, 2008, 372, 356-357.	6.3	6
190	Quality of Life Among HIV-Infected Children in Thailand. Journal of the International Association of Providers of AIDS Care, 2008, 7, 141-147.	1,2	16
191	Hospitalization and Mortality among HIV-Infected Children after Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2007, 44, 599-604.	2.9	122
192	Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2007, 45, 637-642.	2.9	66
193	SUSTAINED IMMUNOLOGIC AND VIROLOGIC EFFICACY AFTER FOUR YEARS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED CHILDREN IN THAILAND. Pediatric Infectious Disease Journal, 2007, 26, 953-956.	1.1	54
194	Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine, 2007, 25, 5324-5329.	1.7	41
195	Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine, 2007, 25, 8257-8261.	1.7	17
196	Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine, 2006, 24, 3095-3099.	1.7	35
197	Immune Reconstitution Syndrome After Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Thai Children. Pediatric Infectious Disease Journal, 2006, 25, 53-58.	1.1	151
198	IMMUNE RECONSTITUTION SYNDROME FROM NONTUBERCULOUS MYCOBACTERIAL INFECTION AFTER INITIATION OF ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV INFECTION. Pediatric Infectious Disease Journal, 2006, 25, 645-648.	1.1	78

#	Article	IF	CITATIONS
199	Disclosure of HIV/AIDS diagnosis to HIV-infected children in Thailand. Journal of Paediatrics and Child Health, 2006, 42, 283-288.	0.4	113
200	Immune Reconstitution Syndrome Due to Bacillus Calmette-Guerin after Initiation of Antiretroviral Therapy in Children with HIV Infection. Clinical Infectious Diseases, 2005, 41, 1049-1052.	2.9	73
201	Efficacy of Highly Active Antiretroviral Therapy in HIV-Infected Children Participating in Thailand's National Access to Antiretroviral Program. Clinical Infectious Diseases, 2005, 41, 100-107.	2.9	149
202	Growth, developmental, and behavioral outcomes of HIV-affected preschool children in Thailand. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88, 1873-9.	0.4	6
203	A mediastinal mass resembling lymphoma: an unusual manifestation of probable case of invasive zygomycosis in an immunocompetent child. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88, 1430-3.	0.4	0
204	Impact of Fluconazole Prophylaxis on Cortisol Levels in Critically III Surgical Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 2471-2476.	1.4	24
205	Epidemiologic, clinical and laboratory features of scrub typhus in thirty Thai children. Pediatric Infectious Disease Journal, 2003, 22, 341-345.	1.1	97
206	An in-house HIV DNA PCR assay for early diagnosis of HIV infection in children in Thailand. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2003, 86, 758-65.	0.4	1